U.S. Finalizes Antidumping Duties on Erythritol from China

Estimated reading time: 4–6 minutes

The U.S. Department of Commerce (Commerce) has issued its final decision on the investigation into erythritol imports from the People’s Republic of China. The agency found that Chinese erythritol is being sold in the United States at less than fair value (LTFV). This ruling applies to imports entering the U.S. between April 1, 2024, and September 30, 2024.

Commerce published its preliminary determination on July 16, 2025. Following a government shutdown that caused delays, the final decision was issued on February 4, 2026. This action was published in the Federal Register on February 10, 2026.

Scope of the Investigation

The investigation covers erythritol, a sugar alcohol used as a sweetener. It includes all physical forms and grades of erythritol, regardless of how it is made or what feedstock is used. The investigation does not cover finished sugar substitute products packaged for retail sale, such as tabletop sweeteners that combine erythritol with other substances like monk fruit or stevia.

Modifications to Scope

Commerce made one change to the product scope from the preliminary phase. After reviewing submitted comments, the agency adjusted the language of the scope. The revised description is available in Appendix I of the published notice.

China-Wide Entity Determination

Commerce continued to apply adverse facts available (AFA) to the China-wide entity. This happened because the agency found the China-wide entity uncooperative and determined that the mandatory respondents were not eligible for a separate rate. Based on AFA, the China-wide entity was assigned a dumping margin of 184.26%.

Separate Rate Companies

Commerce assigned a dumping margin of 85.04% to the following exporters and producers, each of which qualified for a separate rate:

  • Beijing Refine Biology Co., Ltd./Chuzhou Refine Biology Co., Ltd.
  • Hunan Nutramax Inc.
  • Shandong Newnature Biotechnology Co., Ltd./Shandong Sanyuan Biotechnology Co., Ltd.
  • Baolingbao Biology Co., Ltd.

The agency adjusted the cash deposit rate for each firm based on export subsidies credited in a separate countervailing duty (CVD) investigation:

  • Beijing Refine Biology Co., Ltd.: 84.95%
  • Hunan Nutramax Inc.: 84.95%
  • Shandong Newnature Biotechnology Co., Ltd.: 84.95%
  • Baolingbao Biology Co., Ltd.: 84.86%

The China-wide entity is assigned a full antidumping duty rate of 184.26%, with no export subsidy offset applied.

Suspension of Liquidation

Commerce instructed U.S. Customs and Border Protection (CBP) to:

  • Suspend liquidation for entries made on or after July 16, 2025.
  • Discontinue suspension for entries made after January 11, 2026, when provisional measures expired.
  • Resume suspension if the U.S. International Trade Commission (ITC) makes a final affirmative injury determination.

If the ITC finds that imports have caused material injury to the U.S. domestic industry, Commerce will issue an antidumping duty order and require the deposit of duties at the rates listed above.

No Verification Conducted

Commerce did not conduct verification in the investigation. This decision was due to the use of total AFA for the China-wide entity and its findings that the mandatory respondents did not qualify for individual rates.

Petition-Based Rate Calculation

Because Commerce did not find any individually examined companies with valid data apart from AFA, it used petition and surrogate value data to calculate the rate for companies receiving separate rates.

Next Steps

Commerce has notified the ITC of its final determination. The ITC has 45 days to decide whether the U.S. domestic industry has been harmed by the imports. If it finds no injury, all duties will be canceled and deposits refunded. If it finds injury, Commerce will issue an antidumping order.

This determination may be viewed in detail in the Federal Register Volume 91, Issue 27, published on February 10, 2026, including attached appendices and decision memoranda.


Legal Disclaimer

This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.